Cerium Nanosystem Reverses Bone Aging by Sparking Mitochondrial Transfer Between Cells
A cerium-based nanosystem activates autophagy in senescent macrophages, triggering mitochondrial biogenesis and transfer that rescues aged bone stem cells.
Summary
Senile osteoporosis involves senescent bone marrow cells that lose mitochondrial function and osteogenic capacity. Researchers engineered a cerium metal-organic framework loaded with alpha-ketoglutarate (CNS) to treat aged bone defects. CNS activated autophagy in senescent macrophages via the SIRT1-PGC-1α axis, driving new mitochondrial production and intercellular transfer to neighboring stem cells. This rescued stem cell function, shifted macrophages toward anti-inflammatory M2 states, and promoted bone formation in a doxorubicin-induced aging rat model. The findings establish macrophages as previously overlooked mitochondrial donor cells and offer a targeted in-situ strategy to rejuvenate the aging bone microenvironment without the risks of exogenous cell or organelle transplantation.
Detailed Summary
Senile osteoporosis affects over 200 million people worldwide and is driven in part by a deteriorating bone marrow microenvironment in which both mesenchymal stem cells (BMSCs) and macrophages (BMDMs) accumulate damage, lose mitochondrial integrity, and propagate senescence to neighboring cells. Existing therapies targeting only BMSCs have proven insufficient because the surrounding immune milieu remains hostile. This study asked whether senescent macrophages could instead be reprogrammed in situ to become functional mitochondrial donors, rescuing adjacent stem cell osteogenesis without the immune rejection risks of exogenous mitochondrial transplantation.
The team synthesized a ~150 nm octahedral mesoporous cerium metal-organic framework (CeMOF) surface-modified with polyethylenimine and covalently conjugated to alpha-ketoglutarate (α-KG), yielding the cerium nanosystem CNS. CeMOF contributes intrinsic Ce³⁺/Ce⁴⁺ redox cycling to scavenge reactive oxygen species (ROS), while α-KG supplements TCA cycle intermediates and suppresses mTORC1-mediated autophagy inhibition by reducing S6K phosphorylation and sustaining ATG gene expression (ULK1, ATG3, ATG7, ATG16L1). Particle size was confirmed at ~178–184 nm by DLS, mesoporous structure was preserved post-modification by N₂ adsorption-desorption, and successful α-KG grafting was verified by FTIR carbonyl peak at 1680 cm⁻¹ and TGA weight-loss differentials.
In vitro, CNS treatment of senescent BMDMs (S-BMDMs) at 10 μg/mL for 24 h substantially reduced intracellular and mitochondrial ROS (measured by DCFH-DA and MitoSOX Red flow cytometry), restored mitochondrial membrane potential (JC-1 red/green ratio recovery), and elevated ATP production. Ultrastructural TEM confirmed increased autophagosome formation. Transcriptomic profiling (BGI-500 platform) of CNS-treated S-BMDMs revealed significant upregulation of SIRT1-PGC-1α pathway genes, with KEGG and GO enrichment analyses linking autophagy activation to mitochondrial biogenesis. CNS-treated S-BMDMs showed enhanced mitochondrial mass and transferred mitochondria (labeled MitoTracker Deep Red) to co-cultured S-BMSCs (labeled MitoTracker Green), confirmed by confocal microscopy. Transwell experiments using 0.4 μm membranes showed transfer was contact-dependent. Following receipt of healthy mitochondria, S-BMSCs displayed reduced senescence markers, improved osteogenic differentiation, and suppressed adipogenic differentiation.
For in vivo validation, a senescence-accelerated rat model was established by weekly intraperitoneal doxorubicin injections (3 mg/kg) for 4 weeks in 7-week-old rats. A 2 mm × 4.5 mm critical-size femoral defect was then created. CNS implanted into the defect site significantly enhanced bone regeneration compared to blank controls, as assessed by micro-CT. In vivo mitochondrial transfer was confirmed by tail-vein injection of MitoTracker Deep Red-labeled BMDMs into aging rats, with flow cytometry 24 hours later detecting the red-labeled mitochondria inside CD90⁺/CD44⁺ BMSCs from flushed marrow. CNS treatment also shifted macrophage polarization toward anti-inflammatory M2 phenotypes, remodeling the immune microenvironment to further support osteogenesis.
The study reframes senescent macrophages — previously viewed only as disease propagators — as actionable therapeutic targets and potential mitochondrial donors. By coupling antioxidant ROS scavenging with autophagy-driven mitochondrial biogenesis through a single nanocomposite, CNS sidesteps the cold-chain, immune-rejection, and repeated-dosing challenges of exogenous mitochondrial therapies. Limitations include the use of an accelerated rather than naturally aged animal model, and the mechanistic evidence for the SIRT1-PGC-1α pathway rests primarily on transcriptomics without genetic knockout confirmation. Translation to human clinical use will require pharmacokinetic profiling, long-term safety data, and delivery optimization for larger skeletal defects.
Key Findings
- CNS (~150 nm octahedral particles) successfully conjugated α-KG to CeMOF, confirmed by FTIR carbonyl peak at 1680 cm⁻¹ and higher TGA weight loss vs. unmodified CeMOF
- CNS at 10 μg/mL restored mitochondrial membrane potential in senescent macrophages (JC-1 red/green ratio recovery) and significantly reduced mitochondrial ROS by MitoSOX flow cytometry
- Transcriptomic profiling identified SIRT1-PGC-1α axis as the dominant pathway upregulated by CNS in S-BMDMs, driving mitochondrial biogenesis
- Confocal microscopy confirmed intercellular mitochondrial transfer from CNS-treated S-BMDMs (MitoTracker Deep Red) to S-BMSCs (MitoTracker Green) in co-culture; transwell experiments established contact dependence
- In vivo flow cytometry detected MitoTracker Deep Red signal inside CD90⁺/CD44⁺ BMSCs 24 h after tail-vein injection of labeled BMDMs, confirming live mitochondrial transfer in aged rats
- CNS implantation into 2 mm × 4.5 mm femoral defects in doxorubicin-accelerated senescent rats significantly improved bone regeneration vs. blank controls by micro-CT
- CNS shifted macrophage polarization toward anti-inflammatory M2 phenotype and suppressed adipogenic differentiation of S-BMSCs while enhancing osteogenic differentiation
Methodology
The study used in vitro senescent macrophage and BMSC cultures, co-culture and transwell systems, and confocal/flow cytometry to quantify mitochondrial transfer and ROS. An in vivo doxorubicin-induced senescence-accelerated rat model (3 mg/kg/week × 4 weeks, starting at 7 weeks of age) received critical-size femoral defects implanted with CNS. RNA-seq was performed on CNS-treated S-BMDMs using the BGI-500 platform, with KEGG and GO pathway enrichment. Statistical analysis used one-way ANOVA with Student's t-test (GraphPad Prism 8), with significance at p<0.05, p<0.01, p<0.001, and p<0.0001.
Study Limitations
The senescence model used doxorubicin-induced accelerated aging rather than natural chronological aging, which may not fully recapitulate human senile osteoporosis biology. The mechanistic attribution to the SIRT1-PGC-1α axis is based on transcriptomics alone without genetic loss-of-function or rescue experiments to confirm causality. No conflicts of interest were declared, but long-term biocompatibility and pharmacokinetics of cerium-based nanoparticles in vivo remain unstudied in this work.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: